A research study recently published in the American Journal of Gastroenterology explains the role of pancreatic enzyme therapy (PERT) in reducing the frequency of acute pancreatitis (AP) in children suffering from acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP). Dr. Matthew Giefer, pediatric gastroenterologist at Ochsner Children’s Hospital was a contributing author for the publication.
In this retrospective cohort study, involving 356 participants – 270 with ARP and 60 receiving PERT – the impact of PERT on clinical outcomes was assessed. After initiation of PERT, the mean AP annual incidence rate decreased from 3.14 down to 0.71 (p<0.001). The findings revealed that 42% of children on PERT did not experience a subsequent AP episode over an average follow-up period of 2.1 years. Notably, children with a SPINK1 mutation and those with ARP (compared to CP) were less likely to experience an AP episode after initiating PERT.
Timely initiation of pancreatic enzyme replacement therapy (PERT) can serve as a pivotal step in not only managing the symptoms associated with these conditions but also in potentially altering the course of the disease. It’s noteworthy that the research suggests the genetic profile of the patient, including the presence of the SPINK1 mutation, plays a crucial role in the effectiveness of PERT. This underscores the need for personalized medicine approaches in treating pancreatitis and calls for a deeper investigation into genetic markers that may influence treatment outcomes.
Furthermore, the study sheds light on the broader implications of PERT beyond just the reduction of acute pancreatitis episodes. It opens avenues for discussions on its impact on the quality of life of children suffering from ARP and CP, as well as its potential to decrease the economic burden associated with hospitalizations and medical interventions for acute episodes. Given the promising findings, the call for a well-structured clinical trial to rigorously test the efficacy and safety of PERT in a controlled environment is both timely and critical. Such trials could pave the way for developing standardized treatment protocols, ultimately enhancing patient care and outcomes in pediatric pancreatitis.
Dr. Giefer emphasized the potential of PERT in altering the pediatric pancreatitis treatment landscape. "Our findings not only highlight PERT's role in significantly reducing the incidence of acute pancreatitis episodes among children with recurrent or chronic pancreatitis but also underscore the importance of a tailored treatment approach based on genetic markers." Dr. Giefer continued, "this research lays the groundwork for future clinical trials, aiming to optimize treatment strategies and improve the quality of life for these patients who have a disease that has historically been difficult to manage."
###
About Ochsner Health
Ochsner Health is the leading not-for-profit healthcare provider in the Gulf South, delivering expert care at its 46 hospitals and more than 370 health and urgent care centers. For 12 consecutive years, U.S. News & World Report has recognized Ochsner as the No. 1 hospital in Louisiana. Additionally, Ochsner Children’s has been recognized as the No. 1 hospital for kids in Louisiana for three consecutive years. Ochsner inspires healthier lives and stronger communities through a combination of standard-setting expertise, quality and connection not found anywhere else in the region. In 2023, Ochsner Health cared for more than 1.5 million people from every state in the nation and 65 countries. Ochsner’s workforce includes more than 38,000 dedicated team members and over 4,700 employed and affiliated physicians. To learn more about how Ochsner empowers people to get well and stay well, visit https://www.ochsner.org/.
RSS